{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T02:52:19Z","timestamp":1764557539484,"version":"build-2065373602"},"reference-count":76,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Hodgkin lymphoma is a haematological malignancy predominantly affecting young adults. Hodgkin lymphoma is a highly curable disease by current treatment standards. Latest treatment guidelines for Hodgkin lymphoma however imply access to diagnostic and treatment modalities that may not be available in settings with restricted healthcare resources. Considerable discrepancies in Hodgkin lymphoma patient survival exist, with poorer outcomes reported in resources-constrained settings. Resources-stratified guidelines for diagnosis, staging and treatment of Hodgkin lymphoma were derived in an effort to optimize patient outcome provided a given setting of available resources. These guidelines were derived based on the framework of the Breast Health Global Initiative stratifying resource levels in basic, core, advanced and maximal categories.<\/jats:p>","DOI":"10.3390\/ijerph17051783","type":"journal-article","created":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T11:59:36Z","timestamp":1583841576000},"page":"1783","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Resources-Stratified Guidelines for Classical Hodgkin Lymphoma"],"prefix":"10.3390","volume":"17","author":[{"given":"Allan","family":"Relecom","sequence":"first","affiliation":[{"name":"Department of Oncology, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1211 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Federico","sequence":"additional","affiliation":[{"name":"Medical Oncology, CHIMOMO Department, University of Modena and Reggio Emilia, Via Universit\u00e0 4, 41121 Modena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1361-7531","authenticated-orcid":false,"given":"Joseph M.","family":"Connors","sequence":"additional","affiliation":[{"name":"BC Cancer Agency, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC V5Z 1G1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospices Civils de Lyon, 3 Quai des Celestins, 69002 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7265-7691","authenticated-orcid":false,"given":"Irene","family":"Biasoli","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Federal Univsersity of Rio de Janeiro, Av. Pedro Calmon, 550-Cidade Universit\u00e1ria-Rio de Janeiro, RJ 21941-901, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8816-5464","authenticated-orcid":false,"given":"Alden","family":"Moccia","sequence":"additional","affiliation":[{"name":"Oncology Institute of Southern Switzerland (IOSI) Ospedale Regionale di Locarno \u201cLa Carit\u00e0\u201d, Via Ospedale 1 CH-6600 Locarno"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"Groupe d\u2019\u00e9tude des lymphomes de l\u2019adulte, CHU de Lyon HCL-GH Sud, 165 Chemin du Grand Revoyet, 69495 Pierre-Benite Cedex, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"McKee","sequence":"additional","affiliation":[{"name":"Clinical Pathology Unit, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1211 Geneva Switzerland"},{"name":"Facult\u00e9 de M\u00e9decine, Geneva University, Rue Michel-Servet 1, 1206 Gen\u00e8ve, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Miralbell","sequence":"additional","affiliation":[{"name":"Department of Oncology, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1211 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital of Cologne, Karpener Str 62, 50924 Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON M5G 2C1, Canada"},{"name":"Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2306-4974","authenticated-orcid":false,"given":"Peter","family":"Johnson","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Southampton, Southampton S017 1BJ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Cavalli","sequence":"additional","affiliation":[{"name":"Institute of Oncology Research (IOR), Via Vela 6, 6500 Bellinzona, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Delavy","sequence":"additional","affiliation":[{"name":"Institute of Global Health, Faculty of Medicine, University of Geneva, Campus Biotech, Chemin des Mines 9, 1202 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Yves","family":"Dietrich","sequence":"additional","affiliation":[{"name":"Department of Oncology, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1211 Geneva, Switzerland"},{"name":"Facult\u00e9 de M\u00e9decine, Geneva University, Rue Michel-Servet 1, 1206 Gen\u00e8ve, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Flahault","sequence":"additional","affiliation":[{"name":"Institute of Global Health, Faculty of Medicine, University of Geneva, Campus Biotech, Chemin des Mines 9, 1202 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13045-019-0799-1","article-title":"Global, regional and national burden of Hodgkin Lymphoma from 1990 to 2017: Estimates from the 2017 Global Burden of Disease study","volume":"12","author":"Zhou","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Melbye, M., Hjalgrim, H., and Adami, H. (2008). Hodgkin Lymphoma. Textbook of Cancer Epidemiology, Oxford University Press.","DOI":"10.1093\/acprof:oso\/9780195311174.003.0026"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/(SICI)1097-0215(19970207)70:4<375::AID-IJC1>3.0.CO;2-T","article-title":"Epstein-Barr virus-associated Hodgkin\u2019s disease: Epidemiologic characteristics in international data","volume":"70","author":"Glaser","year":"1997","journal-title":"Int. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e2014048","DOI":"10.4084\/mjhid.2014.048","article-title":"Epidemiological Overview of Hodgkin Lymphoma across the Mediterranean Basin","volume":"6","author":"Salati","year":"2014","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_6","unstructured":"SEER (2018, September 29). Cancer Stat Facts: Hodgkin Lymphoma, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4103\/0971-5851.171550","article-title":"Clinical profile and outcome of adult Hodgkin lymphoma: Experience from a tertiary care institution","volume":"36","author":"Maddi","year":"2015","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ijc.28049","article-title":"Hodgkin\u2019s lymphoma mortality in the Americas, 1997\u20132008: Achievements and persistent inadequacies","volume":"133","author":"Chatenoud","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hon.2450","article-title":"Treatment Outcomes for Hodgkin\u2019s Lymphoma: First Report from the Brazilian Prospective Registry","volume":"36","author":"Biasoli","year":"2018","journal-title":"Heamatological Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ijc.31096","article-title":"Lower Socio-economic status is independently associated with shorter survival in Hodgkin Lymphoma patients-An analysis from the Brazilian Hodgkin Lymphoma Registry","volume":"142","author":"Biasoli","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.bjhh.2017.08.001","article-title":"High frequency of primary refractory disease and low progression-free survival rate of Hodgkin\u2019s lymphoma: A decade of experience in a Latin American center","volume":"39","year":"2017","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.6004\/jnccn.2018.0013","article-title":"NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018","volume":"16","author":"Hoppe","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1111\/j.1075-122X.2006.00199.x","article-title":"Breast Cancer in Limited-Resource Countries: An Overview of the Breast Health Global Initiative 2005 Guidelines","volume":"12","author":"Anderson","year":"2006","journal-title":"Breast J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.11604\/pamj.2016.25.99.9736","article-title":"Defining the diagnostic divide: An analysis of registered radiological equipment resources in a low-income African country","volume":"25","author":"Ngoya","year":"2016","journal-title":"Pan Afr. Med. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin Oncol"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.3324\/haematol.2011.045856","article-title":"Management of fertility in patients treated for Hodgkin lymphoma","volume":"96","author":"Harel","year":"2011","journal-title":"Heamatologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S1470-2045(18)30500-X","article-title":"Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin\u2019s lymphoma (RATHL): A secondary analysis of a randomised phase 3 trial","volume":"19","author":"Anderson","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1200\/JCO.2015.62.2860","article-title":"Global Health Equity: Cancer Care Outcome Disparities in High, Middle and Low Income Countries","volume":"34","author":"Hunt","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of Advanced Hodgkin\u2019s Disease with MOPP, ABVD or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7","article-title":"Combination chemotherapy of Hodgkin\u2019s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP","volume":"36","author":"Bonadonna","year":"1975","journal-title":"Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin\u2019s lymphoma: Results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial","volume":"27","author":"Federico","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/annonc\/mdl397","article-title":"ABVD for Hodgkin\u2019s lymphoma: Full-dose chemotherapy without dose reductions or growth factors","volume":"18","author":"Boleti","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1200\/JCO.2005.02.7243","article-title":"Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin\u2019s lymphoma","volume":"23","author":"Martin","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1200\/JCO.1996.14.4.1297","article-title":"Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin\u2019s disease","volume":"14","author":"Hirsch","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2009.23.3239","article-title":"Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin\u2019s Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN","volume":"27","author":"Hoskin","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/annonc\/mdg020","article-title":"Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours","volume":"14","author":"Huddart","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1378\/chest.120.2.617","article-title":"Bleomycin induced pneumonitis","volume":"120","author":"Sleijfer","year":"2001","journal-title":"Chest"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin\u2019s lymphoma (GHSG HD13): An open-label, randomised, non-inferiority trial","volume":"385","author":"Behringer","year":"2015","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","article-title":"Bleomycin in older early-stage favorable Hodgkin lymphoma patients: Analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials","volume":"127","author":"Goergen","year":"2016","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin\u2019s Lymphoma When High-Dose Salvage Is Planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2015.64.5648","article-title":"ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial","volume":"34","author":"Carde","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdu189","article-title":"ABVD (8 cycles) versus BEACOPP (4 escalated cycles \u2265 4 baseline): Final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial","volume":"25","author":"Mounier","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(13)70341-3","article-title":"Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin\u2019s lymphoma: A systematic review and network meta-analysis","volume":"14","author":"Skoetz","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanceed-stage Hodgkin\u2019s lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III and IV Hodgkin\u2019s Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1200\/JCO.2015.62.8412","article-title":"Establishing and Delivering Quality Radiation Therapy in Resource-Constrained Settings: The Story of Botswana","volume":"34","author":"Efstathiou","year":"2016","journal-title":"J. Clin Oncol."},{"key":"ref_38","unstructured":"International Atomic Energy Agency (2018, November 28). Planning Radiotherapy Health Services: A Practical Tool, IAEA Human Health Series N\u00b0 14. Available online: https:\/\/www.pub.iaea.org\/MTCD\/Publications\/PDF\/Pub1462_web.pdf."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1200\/JCO.2006.07.0482","article-title":"Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin\u2019s lymphoma: Final results of the GHSG HD7 trial","volume":"25","author":"Engert","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC\/LYSA\/FIL H10 Trial","volume":"35","author":"Girinsky","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1111961","article-title":"ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin\u2019s Lymphoma","volume":"366","author":"Meyer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3324\/haematol.2009.015644","article-title":"Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin\u2019s lymphoma: A systematic review","volume":"95","author":"Herbst","year":"2010","journal-title":"Haematologica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced Treatment Intensity in Patients with Early-Stage Hodgkin\u2019s Lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1182\/blood-2004-04-1311","article-title":"Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease","volume":"104","author":"Straus","year":"2004","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin\u2019s Lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: Risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.2012.47.9774","article-title":"Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: An analysis of the german hodgkin study group","volume":"31","author":"Wongso","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin\u2019s lymphoma: A report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose\u2013Positron Emission Tomography Imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted Treatment Guided by Interim PET-CT scan in Advanced Hodgkin\u2019s Lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): Final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2018","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): A randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casanovas","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_53","first-page":"2246","article-title":"Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin\u2019s disease: Results of the Groupe d\u2019\u00e9tudes des Lymphomes de l\u2019Adulte H89 trial","volume":"95","author":"Sebban","year":"2000","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa022628","article-title":"Involved-field radiotherapy for advanced Hodgkin\u2019s lymphoma","volume":"348","author":"Aleman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1200\/JCO.1998.16.3.818","article-title":"Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin\u2019s disease. International Database on Hodgkin\u2019s Disease Overview Study Group","volume":"16","author":"Loeffler","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1200\/JCO.2004.01.021","article-title":"Consolidation Radiation After Complete Remission in Hodgkin\u2019s Disease Following Six Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Chemotherapy: Is There a Need?","volume":"22","author":"Laskar","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.2009.26.0323","article-title":"Consolidation Radiotherapy in Patients with Advanced Hodgkin\u2019s Lymphoma: Survival Data from the UKLG LY09 Randomized Controlled Trial (ISRCTN97144519)","volume":"28","author":"Johnson","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMra1003733","article-title":"Early-Stage Hodgkin\u2019s Lymphoma","volume":"363","author":"Armitage","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Kuruvilla, J. (2009). Standard therapy of advanced Hodgkin lymphoma. Hematol. Am. Soc. Hematol. Educ. Program., 497\u2013506.","DOI":"10.1182\/asheducation-2009.1.497"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1200\/JCO.1999.17.2.534","article-title":"Autotransplants for Hodgkin\u2019s Disease in Patients Never Achieving Remission: A Report from the Autologous Blood and Marrow Transplant Registry","volume":"17","author":"Lazarus","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1200\/JCO.1999.17.12.3776","article-title":"Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients with Non-Hodgkin\u2019s Lymphoma","volume":"17","author":"Moskowitz","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: Results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: A randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"ref_65","first-page":"60165","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"6736","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1080\/10428190802304974","article-title":"Allogeneic hematopoietic cell transplantation for Hodgkin lymphoma: A concise review","volume":"49","author":"Laport","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1200\/JCO.2007.13.2415","article-title":"Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin\u2019s lymphoma: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Sureda","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood.V128.22.1110.1110","article-title":"Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed\/Refractory Classical Hodgkin Lymphoma","volume":"128","author":"Timmerman","year":"2016","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed\/Refractory Classic Hodgkin Lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.1997.15.2.528","article-title":"Outcome of patients with Hodgkin\u2019s disease failing after primary MOPP-ABVD","volume":"15","author":"Bonfante","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","article-title":"Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma","volume":"31","author":"Moskowitz","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2000.18.13.2615","article-title":"Gemcitabine in the Treatment of Refractory Hodgkin\u2019s Disease: Results of a Multicenter Phase II Study","volume":"18","author":"Santoro","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.1998.16.2.584","article-title":"Vinblastine for recurrent Hodgkin\u2019s disease following autologous bone marrow transplant","volume":"16","author":"Little","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2005.05.022","article-title":"Salvage Radiotherapy in Patients with Relapsed and Refractory Hodgkin\u2019s Lymphoma: A Retrospective Analysis from the German Hodgkin Lymphoma Study Group","volume":"23","author":"Josting","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0936-6555(94)80051-0","article-title":"The effectiveness of radiotherapy for localized relapse in patients with Hodgkin\u2019s disease (IIB-IVB) who obtained a complete response with chemotherapy alone as initial treatment","volume":"6","author":"MacMillan","year":"1994","journal-title":"Clin. Oncol."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/17\/5\/1783\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:05:36Z","timestamp":1760173536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/17\/5\/1783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,9]]},"references-count":76,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["ijerph17051783"],"URL":"https:\/\/doi.org\/10.3390\/ijerph17051783","relation":{},"ISSN":["1660-4601"],"issn-type":[{"type":"electronic","value":"1660-4601"}],"subject":[],"published":{"date-parts":[[2020,3,9]]}}}